Moneycontrol Be a Pro
Get App
Last Updated : Jul 23, 2019 05:23 PM IST | Source: Moneycontrol.com

Dhanuka Agritech Q1: Soft quarter as monsoon clouds the show

Representative Image
Representative Image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Highlights

  • Delay in monsoon and sowing impacts June sales

  • High raw material costs eat up profit margin

  • Volume growth remains muted, price hike drives revenue

  • Controlled sales overhead positive for EBIT

  • New product launches to drive growth


Dhanuka Agritech (DHAN) reported another subdued quarter with continued pressure on margins. Delay in monsoon impacted the June sales for the company, which is expected to spill over to the current quarter.

dhanuka1

Key positives

Close

- Earnings before interest, tax, depreciation and amortisation (EBITDA) margin improved 185 basis points (bps) year-on-year (YoY) due to the controlled sales expenses and lower overheads.

Key negatives

-Delay in the onset of monsoon and sowing impacted the agrochemical business in June due to which the topline growth for the company remained largely muted at 3 percent YoY.

-While volume growth remained largely tepid, the marginal uptick in revenue was driven by its price increase in order to partially pass on the uptick in raw material costs.

- High cost inventory coupled with increase in competition led to a 110 basis points (bps) contraction in the gross margin.

Other comments

-Dhanuka has six new products which are to be launched this year, of which three have already been launched. Traction from these new launches is expected to support top line in coming quarters. However, gains from the product mix improvement have been negated by higher technical prices and lower demand (due to deficient monsoon).

-The company is revamping its marketing network to accelerate overall business growth. It is focusing more on high revenue generating customers via its Kohinoor scheme and also weeding out uncompetitive dealers.

-Dhanuka Laboratories, a promoter group entity, has successfully bid for Orchid Pharma through the National Company Law Tribunal (NCLT) auction for an estimated Rs 600 crore. The management has guided that promoters will pledge a part of its stake in the company to fund this acquisition.

Outlook

The stock has corrected 39 percent from its 52-week high. After the correction, the stock is trading at an FY20 estimated price-to-earnings of 14.7 times.

dhanuka2

While the improving product mix is a positive for the long-term growth for the company, the high raw material prices and unpredictable monsoon are impacting the performance negatively. Monsoon performance in the current quarter (Q2) would be something to watch out for.

Follow @Ruchiagrawal

For more research articles, visit our Moneycontrol Research Page



Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Jul 23, 2019 04:05 pm
Loading...
Sections
Follow us on
Available On